NDATOPICALLOTION
Approved
Feb 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
SKLICE (ivermectin) by R-Pharm US is 12. First approved in 2012.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SKLICE is a topical ivermectin 1% cream approved in 2012 for the treatment of rosacea lesions. The mechanism of action remains unknown, though ivermectin is traditionally an antiparasitic agent. It is applied topically once daily as a lotion formulation.
Peak
Product is in peak lifecycle stage, indicating stable commercial operations but limited growth opportunities; team size and expansion potential are constrained.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of ivermectin cream in treating rosacea lesions is unknown. 12.2 Pharmacodynamics Cardiac Electrophysiology At therapeutic doses, ivermectin cream is not expected to prolong QTc interval. 12.3 Pharmacokinetics Absorption The absorption of ivermectin…
Pharmacologic Class:
Antiparasitic
Indications
Worked on SKLICE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.